Back to discover
Disease
Failure to Thrive
Late-stage therapeutic developmentEmerging research
1
Publications
2
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
Research2023-11-01The New England journal of medicine
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
No activity recorded in this window. Try a wider timeframe.
Clinical trials
The current development programme across all trial phases.
Clinical programme
2
0
1
1
Late-stage studies
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes3
- Gastroenteritis1
- Immune Checkpoint Inhibitors1
- Neoplasms1
Leading journals1
- The New England journal of medicine1
Leading researchers8
- Amant F1
- Baarslag MA1
- Beijnen JH1
- Borgers JSW1
- Buitelaar PLM1
- de Groot JWB1
- Gierenz N1
- Haanen JBAG1
Affiliations (unnormalised)1
- Amalia Children's Hospital1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A condition of substandard growth or diminished capacity to maintain normal function.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.